EA3 study: Diabetic Kidney Disease and Rare Kidney Disease study and data in Sandbox
PreviousEA3 study: Women’s health – PCOS and infertility study, and data in SandboxNextEA3 study: Oncology studies
Last updated
Was this helpful?
Last updated
Was this helpful?
If you wish to use EA3 data, please familiarize yourself with these instructions.
/finngen/library-red/EA3_DIAB_2.0/
Previous versions
/finngen/library-red/EA3_DIAB_1.0/
Expansion Area 3 (EA3) studies aim to acquire additional clinical data centered around specific diseases through biobanks.
Aim: The Diabetic Kidney Disease (DKD) and Rare Kidney Disease (RKD) deep phenotyping study aimed to capture in depth information on individuals with diabetes and RKD by improving our understanding of clinical and genetic diabetes segmentation/clusters and their propensity for subsequent complications. Furthermore, the study aimed to investigate the clinical and genetic correlates of DKD, diabetic complications, and hard outcomes (peripheral vascular diseases, mortality) within these segments/clusters, as well as discover protective and risk factors for RKD and its complications (renal failure, dialysis).
Methods: Data was captured from six biobanks; Auria, Helsinki, Tampere, Borealis, Central Finland and Eastern Finland biobanks. Laboratory database searches were done for relevant biomarkers (blood glucose, c-peptide, islet cell, and other diabetes related antibodies, lipids, liver enzymes, markers for renal function/damage, covid-19 testing, autoimmune antibodies, amylase, f-elastase, etc), as well as for inpatient drugs and therapies, and physiological measurements.
Data: The Diabetic Kidney Disease (DKD) and Rare Kidney Disease (RKD) data has been placed in the Sandbox and is available for analysis. The DKD and RKD samples are from DF11 and has been collected from 6/6 hospital biobanks. Data collection time until 31.10.2022.
Summary of the data (Oct 2023):
